GSK: FDA grants priority review of belantamab mafodotin for patients with relapsed or refractory…
GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) granted a priority review for the company’s Biologics License Application (BLA) seeking approval of belantamab…
Read More...
Read More...
